Drugs and Devices

FDA approves new COPD treatment

On July 23, the U.S. Food and Drug Administration (FDA) approved Tudorza Pressair (aclidinium bromide) for the long-term maintenance treatment of bronchospasm in patients with chronic obstructive pulmonary disease. Read more.


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Shares